MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
P/E ratio for MyMD Pharmaceuticals, Inc. (MYMD)
P/E ratio as of 2023: -2.99
According to MyMD Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.99. At the end of 2022 the company had a P/E ratio of -2.95.
P/E ratio history for MyMD Pharmaceuticals, Inc. from 2005 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.99 |
| 2022 | -2.95 |
| 2021 | -7.10 |
| 2020 | -1.31 |
| 2019 | -0.50 |
| 2018 | -68.58 |
| 2017 | -13.15 |
| 2016 | -187.39 |
| 2015 | -40.08 |
| 2014 | -363.30 |
| 2013 | -345.74 |
| 2012 | -154.29 |
| 2011 | -96.50 |
| 2010 | -263.46 |
| 2009 | -51.97 |
| 2008 | -246.47 |
| 2007 | -76.48 |
| 2006 | -12.54 |
| 2005 | -23.53 |